Cosmos Health Inc. Stock Price, News & Analysis

Cosmos Health (NASDAQ:COSM) has filed a new patent application (N2039646) for allergic inflammation therapy, developed through AI drug repurposing in collaboration with Cloudpharm and the National Hellenic Research Foundation. The patent leverages their AI-powered Cloudscreen platform and experimental data to repurpose an existing marketed drug, targeting key inflammatory pathways through a novel mechanism.

The initiative addresses a significant market opportunity, as allergic conditions affect 10-30% of the global population according to BMJ Open 2024. The global allergy treatment market, valued at $23.5 billion in 2024, is projected to reach $37.0 billion by 2033, growing at a CAGR of 4.92%.

Cosmos Health (NASDAQ:COSM) has expanded its exclusive distribution agreement with Virax Biolabs for Avian Influenza Virus Real-Time PCR Kits to include Saudi Arabia, UAE, Qatar, and Kuwait. This expansion follows the previous agreement announced on January 13, 2025, which was to Oman and Bahrain. Under the new agreement, Cosmos Health gains authorization to import, sell, and distribute ViraxClear-branded kits throughout all GCC countries.

Cosmos Health (NASDAQ:COSM) has secured buy-out rights and exclusive licensing for two WIPO-patented anticancer drugs targeting prostate, ovarian, and colorectal cancers. The patents, valued at approximately $24.61 million by a global audit firm, can be acquired for $7.81 million, potentially adding $16.80 million to the Company's net worth.

The first therapy is protected by WIPO patent WO 2017/001439, valid in the EU, USA, Canada, Japan, China, and Australia. The second therapy is covered by EU patent EP3484892 and filed under WO 2018/011414 A1. Both therapies are set to begin Clinical Phase I trials.

The target markets show significant growth potential, with projections for 2030 including: ovarian cancer drug market reaching $6.3 billion (14.6% CAGR), prostate cancer therapeutics reaching $21.48 billion (8.4% CAGR), and colorectal cancer therapeutics achieving $16.7 billion (4.7% CAGR).

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas has acquired 647,809 common shares valued at $425,000 through six transactions between December 20, 2024, and January 17, 2025. Following these purchases, Siokas's beneficial ownership in the company has increased to 4,164,789 common shares.

The CEO expressed enthusiasm about the company's future prospects and highlighted his continued commitment, noting his total personal investment of over $17 million since the company's inception. Siokas emphasized that Cosmos Health is at a transformative moment, focusing on advancing their strategy, driving projects forward, and expanding their brands globally.

Cosmos Health (NASDAQ:COSM) has secured a distribution agreement with Virax Biolabs for Avian Influenza Virus (AIV) Real-Time PCR Kits. The agreement grants exclusive distribution rights in Greece and Cyprus, along with non-exclusive rights in 12 European countries and 2 GCC nations (Oman and Bahrain).

The RT-PCR tests detect RNA from AIV, including H5, H7, and H9 subtypes, particularly the H5N1 strain. These kits enable healthcare professionals to quickly identify infections in individuals exposed to infected livestock or high-risk environments. Under the agreement, Cosmos Health will handle import, sales, and distribution, while Virax will manage regulatory compliance and documentation for product approvals.

The partnership aims to enhance global preparedness against avian influenza outbreaks by providing specialized testing capabilities that can differentiate between various strains, supporting rapid response and intervention in healthcare systems.

Cosmos Health (NASDAQ:COSM) has appointed Professor Dimitrios Trafalis, MD, as Head of Oncology at its Research and Development division. Professor Trafalis, currently serving at the National and Kapodistrian University of Athens, brings expertise in oncology-hematology, cancer cytogenetics, and personalized cancer therapies. He will lead research initiatives focusing on preclinical and clinical development strategies, regulatory support, and cutting-edge oncology studies.

As a specialist in biosciences, cancer research, and drug development, Professor Trafalis has authored multiple scientific publications and received numerous citations and international research grants. In his new role, he will oversee preclinical and clinical protocols while presenting key developments at global medical conferences and in scientific journals.

Cosmos Health (NASDAQ:COSM) announced that CEO Greg Siokas and CFO George Terzis have increased their stake in the company by approximately 343,122 common shares, valued at $200,000. Mr. Siokas acquired 257,334 shares worth $150,000, while Mr. Terzis purchased 85,778 shares valued at $50,000.

The CEO expressed disappointment in the current share price, which he believes is below the company's intrinsic value, but views it as an opportunity for increased investment. He highlighted the company's assets, including growing proprietary brands, a pharmaceutical GMP license for contract manufacturing, and an R&D team working on cancer and obesity treatments.

Taglich Brothers has released an updated research report on Cosmos Health (NASDAQ:COSM), maintaining a Speculative Buy rating with a $3 price target. The report projects 25% revenue growth to $68.4 million in FY 2025, up from an estimated $54.7 million in FY 2024. The company expects significant improvements in financial metrics, including gross margin expansion to 19.4% and positive EPS of $0.01 in 2025. Growth drivers include Cana Laboratories investments, projected to generate over $10 million in annual gross profit at full capacity, and expanded distribution agreements across Europe and Middle East. The company's stock currently trades at 0.2x sales, below the sector average of 2.1x.

Cosmos Health (NASDAQ:COSM) has announced the integration of Bitcoin and Ethereum as part of its treasury reserve assets. This strategic move aligns with the company's investment in new technologies, following their recent acquisition of Cloudscreen, an AI-driven drug repurposing platform. The company aims to diversify its balance sheet through cryptocurrency and blockchain-related assets, anticipating potential upside as these digital assets gain wider adoption. Additionally, Cosmos Health plans to accept cryptocurrency payments from customers.